VYEPTI is indicated for the preventive treatment of migraine in adults. View patient site
VYEPTI is indicated for the preventive treatment of migraine in adults.

From the American Headache Society position statement update, 2024

Real-world studies include both prospective and retrospective studies. Although the evidence provided by these studies is not considered to be of the same quality as randomized control trials (RCTs), they are very useful in that they generally confirm the results of the RCTs regarding efficacy, tolerability, and safety, and they do so within a wide variety of international cohorts, often over longer time periods.1

Real-world evidence icon

REVIEW study: exploring patient experience with VYEPTI

Patient group icon

This observational, real-world study was designed to assess satisfaction with VYEPTI effectiveness, infusion experience, and clinical impact from both patient and physician perspectives in day-to-day healthcare settings. The results below reflect the personal interpretation of each survey question from 94 patients with chronic migraine who had 6 or more months of treatment with VYEPTI.2

Survey icon

Patients were asked to compare their experience with migraine before and after starting VYEPTI. Survey responses were dependent on patient recall and may have been further impacted by the span of time from diagnosis up through treatment cycles with VYEPTI. Safety data were not collected for the study; any adverse events were collected via standard reporting methods.2 Please see VYEPTI safety and tolerability data to learn more. See select study design details and additional study limitations below.

Explore the VYEPTI pivotal trials and 2-year patient-reported outcomes data to see if VYEPTI could be right for your patients.

Read full clinical publicationLink out icon

For REVIEW, 3 components comprised the study: a structured patient survey intended to measure their satisfaction with VYEPTI, a retrospective chart review, and a semi-structured healthcare provider interview. Study data reflect patients' experiences with migraine treatment and their migraine symptomatology collected across 4 study sites in the US. Data are survey-based and dependent upon patient recall. Descriptive statistics were used; no conclusions can be drawn.2,3

To participate, patients must have completed a minimum of 2 consecutive infusion cycles (≥6-month exposure) with 51% of patients having received 5 or more at the time of the survey. Patients were not excluded based on comorbidities.

The structured patient survey underwent linguistic validation to ensure that patients understood the intent of each question.2

Select baseline characteristics

  • Mean age: 49.2 years (median: 49 years)
  • Mean time since diagnosis: 15.4 years (median: 12 years)
  • Current VYEPTI dose: 57% 300 mg | 23% 100 mg | 19% cannot recall/missing/other
  • 100% of respondents had prior preventive treatment: 89% anti-CGRP mAb | 82% OnabotulinumtoxinA | 74% oral preventive | 73% Gepant

Select inclusion criteria

  • Over 18 years of age
  • Diagnosis of chronic migraine (per the patient’s chart)
  • Received ≥2 consecutive VYEPTI infusion cycles
  • Ability to complete survey in English

Exclusion criteria

  • Treated with VYEPTI in a clinical trial setting
  • Enrolled in another clinical trial for migraine

Limitations

  • Patient data were survey-based, self-reported, and dependent on patient recall
  • Patient population selected based on treatment with VYEPTI regardless of prescribed dosage, suggesting positive responses and tolerability
  • No cross-comparisons were conducted among outcome measures for the 100 mg, 200 mg, or 300 mg doses
  • Gepants were not excluded, and methodology did not support differentiation between preventive and acute use
  • Inherent selection bias in the study could not be mitigated
  • Results are descriptive data; no formal statistical analyses were performed

CGRP, calcitonin gene-related peptide; mAb, monoclonal antibody.

VYEPTI from the perspective of your peers

Examining the burden of chronic migraine and a clinical case study

"It’s so important for us to really understand what our patients experience and how we can provide support both emotionally and clinically."

Wade Cooper, DO

Treating chronic migraine, illustrated by a patient case study

"We'll dig deeper into the VYEPTI patient reported outcomes data as reported in the clinical trials."

Peter McAllister, MD FAAN

Voices of VYEPTI

Learn about the personal experience from patients prescribed VYEPTI

Despite being on a preventive and an acute treatment, migraine dictated Chanci’s daily life

  • Inability to be present with friends and family
  • Isolated due to light and noise sensitivity
  • Frequent migraine days as well as daily headaches
  • Migraine attacks increasing in frequency and severity despite taking preventive medication
  • Increased use of acute medication without relief

Her neurologist recognized a change was needed and prescribed VYEPTI

REVIEW PATIENT IMPACT DATA
Chanci, 33, is a mother, wife, artist, and real VYEPTI patient

“My migraine attacks made me feel helpless. I needed to do something different. My neurologist and I decided to try VYEPTI.”

VYEPTI v
Chanci, real VYEPTI patient

Patient results may vary.

50% icon

of ~1,100 people with migraine surveyed in 2021 were dissatisfied with their ability to control their disease.4††

††Survey consisted of people diagnosed with migraine disease for ≥2 years and who satisfy at least 1 of the following: ≥8 migraine attacks in the prior month, have been prescribed a preventive migraine treatment, or are either currently taking or have previously taken a preventive migraine treatment.

Hear from more patients who were moved to VYEPTI

Lou, Lealani, and Electra, real VYEPTI patients
Lou, real VYEPTI patient

“When I would have my migraine attacks, my life was on hold. My experience on VYEPTI has given me the opportunity to do the things I used to do. It’s given me a second chance at life.”

Lou is a former college athlete whose chronic migraine slowed her down. Then her doctor prescribed VYEPTI.

VYEPTI v
Lou, real VYEPTI patient
Lealani, real VYEPTI patient

“It has caused me to lose jobs...not experience things with my family. I almost missed my own wedding. Before VYEPTI, I could not write things on a calendar and expect to keep them.”

Lealani had a hard time planning anything because chronic migraine kept getting in the way. Then she read about VYEPTI and asked her doctor.

VYEPTI v
Lealani, real VYEPTI patient
Electra, real VYEPTI patient

“I've just kind of been living day by day. I told myself, I can't keep living like this. There has to be something that can help me.”

Electra was struggling with chronic migraine and joined the VYEPTI clinical trial. Once it was approved, she started treatment.

VYEPTI v
Electra, real VYEPTI patient
June, Nicole, and Cynthia, real VYEPTI patients
June, real VYEPTI patient

“My infusion experience has been positive. I go to an infusion center. It’s just 30 minutes. I lay back and relax. They come and check on me and I’m done.”

June is a long-time chronic migraine sufferer whose chronic migraine negatively affected her relationship with her granddaughter. Then she and her doctor decided to try VYEPTI.

VYEPTI v
June, real VYEPTI patient
Nicole, real VYEPTI patient

“I no longer spend endless time tracking every trigger and medication I am taking, so my time is freed up to do more of the things that I love.”

A passionate patient advocate who struggled to engage with life like she wanted because of chronic migraine, Nicole worked with a doctor to start VYEPTI after several failed treatments.

VYEPTI v
Nicole, real VYEPTI patient
Cynthia, real VYEPTI patient

“I actually love knowing that 100% of the infusion is going into my bloodstream—that VYEPTI is completely going into my body."

Cynthia struggled with chronic migraine with brain fog that got in the way of her pursuing her goals. Then she asked her doctor about VYEPTI, despite her hesitancy about an IV infusion.

VYEPTI v
Cynthia, real VYEPTI patient

All real VYEPTI patients on this page were compensated for their time. Patient results may vary

IMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI
in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and institute appropriate therapy.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including VYEPTI, in the postmarketing setting. Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension, and in some cases hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation. The CGRP antagonist was discontinued in many of the reported cases.

Monitor patients treated with VYEPTI for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of VYEPTI is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.

Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists. In reported cases with monoclonal antibody CGRP antagonists, symptom onset occurred a median of 71 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms.

VYEPTI should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

For more information, please see the Full Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI
in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and institute appropriate therapy.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including VYEPTI, in the postmarketing setting. Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension, and in some cases hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation. The CGRP antagonist was discontinued in many of the reported cases.

Monitor patients treated with VYEPTI for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of VYEPTI is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.

Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists. In reported cases with monoclonal antibody CGRP antagonists, symptom onset occurred a median of 71 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms.

VYEPTI should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

For more information, please see the Full Prescribing Information and Patient Information.

References:

  1. Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;00:1-9. doi:10.1111/head.14692
  2. Argoff C, Herzog SP, Smith RM, Kotak SV, Sopina L, et al. Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study. J Headache Pain. 20024;25:65:1-13.
  3. Data on file. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.
  4. National Headache Foundation. Preventing migraine attacks: a current perspective. April 2021. Accessed May 25, 2023. https://headaches.org/wp-content/uploads/2021/05/NHF-Preventing-Migraine-Attacks-Report-Updated-Reference-2021MAY10.pdf
Site map Terms of Use Privacy Policy Contact us Cookie settings

© 2025 Lundbeck. All rights reserved. VYEPTI and VYEPTI CONNECT are registered trademarks of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-101196v6

All trademarks, logos, and brand names are the property of their respective owners. All company, product, and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.

This website is intended for US healthcare professionals only.